Cyclobenzaprine Hcl
Brand names: Amrix, Cyclobenzaprine Hcl, Cyclobenzaprine Hcl Er
At a glance
- Medicare prescriptions, 2024
- 6,219,301
- Medicare drug cost
- $54.9M
- Average cost per prescription
- $8.82
- Clinicians who prescribed it
- 162,993
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
1. Indications and Usage Cyclobenzaprine hydrochloride extended-release capsules are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion. Limitations of Use: Cyclobenzaprine hydrochloride extended-release capsules should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride extended-release capsules have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease or in children with cerebral palsy.
From the FDA-approved prescribing information (label dated December 2024). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 28.1%
- Nurse Practitioners 23.7%
- Internal Medicine 16.4%
- Physician Assistants 11.1%
- Pain Medicine 6.3%
- Rheumatology 2.0%
- Physical Medicine & Rehabilitation (PM&R) 1.6%
- Emergency Medicine 1.6%
- Neurology 1.5%
- Orthopedic Surgery 1.4%
- General Practice 1.1%
- Anesthesiology 0.8%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 38% from 2019 to 2024.
Biggest change by state since 2019
- North Dakota +64%
- Alabama +60%
- Rhode Island +59%
- Hawaii +55%
- Minnesota +54%
- Puerto Rico (smallest change) +8%
- Maine (smallest change) +20%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 3 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Advanced Rx Pharmacy of Tennessee, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 15 mg | orange capsule, 14 mm | B15 |
Direct_rx
| Strength | Looks like | Imprint |
|---|---|---|
| 15 mg | orange capsule, 14 mm | 15 MG C CEPHALON |
Phoenix Rx LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 7.5 mg | white round tablet, 7 mm | C 735 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.